COCHHealthcare · Medical DevicesThe 2 Wall Street analysts covering Envoy Medical, Inc. hold a median 12-month price target of $2 — +166.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Envoy Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (81): Smaller than most of the companies we track.
Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on COCH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +166.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 July 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | $2.00 |
| 15 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $2.50 |
| 15 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Mar 2026 | HC Wainwright & Co. | Initiates | Buy | $2.50 |
| 31 Mar 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 27 May 2025 | Ascendiant Capital | Maintains | Buy | — |
| 21 Apr 2025 | Ascendiant Capital | Maintains | Buy | — |
| 6 Dec 2024 | Ascendiant Capital | Maintains | Buy | — |
| 14 Oct 2024 | Brookline Capital | Initiates | Buy | — |
| 3 Sept 2024 | Ascendiant Capital | Maintains | Buy | — |
| 24 June 2024 | Ascendiant Capital | Initiates | Buy | — |
| 3 Apr 2024 | Lake Street | Maintains | Buy | — |
| 21 Dec 2023 | Northland Capital Markets | Initiates | Outperform | — |
| 28 Nov 2023 | Lake Street | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COCH appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 80% of US stocks
Cheaper than 3% of US stocks
Cheaper than 7% of US stocks
Cheaper than 70% of US stocks
Higher than 8% of US stocks
Higher than 22% of US stocks
Higher than 1% of US stocks
Higher than 2% of US stocks
Higher than 1% of US stocks
Higher than 99% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Envoy Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Envoy Medical reported a quarterly loss of $0.07 per share, narrower than the Zacks Consensus Estimate of a $0.09 loss and an improvement from the $0.32 per-share loss a year earlier.
Why it matters — The narrower-than-expected loss and the year-over-year improvement provide COCH watchers with a clear data point on the company's most recent quarterly performance.
Envoy Medical reported second quarter 2026 financial results and provided a business update. Subsequent to the quarter's end, the company submitted the first module of its Modular PMA application to the FDA, and reported positive 12-month Stage 1 data showing continued improvement in speech perception for its fully implanted cochlear implant.
Why it matters — These regulatory and clinical milestones signal progress toward bringing Envoy Medical's fully implanted cochlear implant to market.
The 2 Wall Street analysts covering Envoy Medical, Inc. have a median 12-month price target of $2, with estimates ranging from $2 to $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Envoy Medical, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Envoy Medical, Inc. 34 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Envoy Medical, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (81 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +166.9% from the last close, and Ticker Nerd's factor model ranks Envoy Medical, Inc. 34 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Envoy Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COCH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.
Envoy Medical, Inc. returned -36.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Envoy Medical, Inc. operates in the healthcare sector, specifically focusing on the design and development of innovative medical devices aimed at improving hearing healthcare.
The most recent item we track (Zacks Investment Research, 10 Aug 2026): "Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue Estimates". Envoy Medical reported a quarterly loss of $0.07 per share, narrower than the Zacks Consensus Estimate of a $0.09 loss and an improvement from the $0.32 per-share loss a year earlier.
Envoy Medical, Inc. operates in the healthcare sector, specifically focusing on the design and development of innovative medical devices aimed at improving hearing healthcare. The company's flagship products are designed to provide advanced solutions for individuals experiencing hearing loss through cutting-edge technology that enhances auditory performance. Envoy Medical, Inc. is known for leveraging its expertise to improve patient outcomes and deliver a better quality of life for those with hearing impairments. Positioned within the broader medical device industry, Envoy impacts various healthcare sub-sectors, including audiology and otolaryngology. Through its dedication to research and development, the company plays a significant role in pushing the boundaries of what is possible in hearing health technologies. Its contributions are important for both patients and healthcare providers, offering novel solutions that integrate seamlessly into medical practices worldwide. With a commitment to innovation, Envoy Medical, Inc. continues to be a key player in the transformation of auditory healthcare, striving to address the needs of a growing demographic requiring sophisticated hearing aid solutions.
CEO Mr. Brent T. Lucas Esq. · 43 employees · United States · https://www.envoymedical.com